Nebenwirkungen · Ratiograstim
Ratiograstim 30 MIU/0.5 mL solution for injection/infusion Ratiograstim 48 MIU/0.8 mL solution for injection/infusion · Abschnitt 4.8 · PDF-Seite 14–15
HOS-118592 · Präparat HOS-094847
14 Hypersensitivity-type reactions including anaphylaxis, rash, urticaria, angioedema, dyspnoea and hypotension occurring on initial or subsequent treatment have been reported in clinical studies and in post-marketing experience. Overall, reports were more common after IV administration. In some cases, symptoms have recurred with rechallenge, suggesting a causal relationship. Ratiograstim should be permanently discontinued in patients who experience a serious allergic reaction.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-15T11:04:00Z · SHA-256 09666c388f6272f1c84ce9bc94c88e838b019fcdb43e89163fe018384d489e13 · Passage 18036c990725d1bf1a020ab06c5cb8665b9a0102053ea4ae6b410276e2a079e0 · Zeichen 8406–8889 im Abschnitt